Phase 2 Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been newly diagnosed with acute myeloid leukaemia (AML), confirmed through bone marrow testing.
• People who have completed a full set of specialised leukaemia tests covering the appearance of cells, cell markers, chromosomes, and gene changes.
• People aged 18 years or older.
• People whose general physical fitness and ability to carry out daily activities falls within an acceptable range, as assessed using a standard medical scale (ECOG score of 0–2).
• People whose blood test on day 6 of treatment shows at least 1% leukaemia blast cells circulating in the blood (confirm with trial site).
• People whose kidneys are functioning well enough to meet a specific minimum level, measured by a standard calculation or urine test.
• People whose liver is functioning within acceptable limits based on blood test results, unless any abnormality is considered to be caused by the leukaemia itself.
• People whom the treating doctor considers suitable to receive a specific chemotherapy regimen used in this trial (DA or IA therapy).
• People who have read, understood, and signed the informed consent form for the trial.

Who may not be able to join:

• People whose AML is the specific subtype known as acute promyelocytic leukaemia (APL).
• People diagnosed with a mixed-type acute leukaemia (MPAL), where the leukaemia cells show features of more than one blood cell type.
• People whose AML has spread to the brain or spinal cord.
• People whose AML has spread to areas outside the bone marrow, forming disease in other parts of the body.
• People with significantly reduced kidney or liver function beyond the limits described in the eligibility requirements.
• People with serious heart conditions, such as heart failure, a recent heart attack, or significant problems with how the heart functions.
• People who currently have another active cancer in another part of the body (people with a history of a cancer that has been fully cured may still be considered eligible — confirm with trial site).
• People with active tuberculosis, or people who are HIV-positive.
• People who have another blood or bone marrow disorder at the same time.
• People who are pregnant or currently breastfeeding.
• People who are unable to understand or follow the requirements of the study.
• People who have a known allergy or sensitivity to any of the medications used in this trial.
• People who are unable to swallow oral (tablet or capsule) medication, or who have a condition that affects the body's ability to absorb medication properly.
• People with an infection that is not currently under control.
• People who have previously been treated with a drug called venetoclax, or who are currently taking part in another clinical trial involving an experimental treatment.

Important: Always verify eligibility with the trial site directly before applying.